Kymera Therapeutics, Inc. business relationships

Companies named in Kymera Therapeutics, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Kymera Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 5.2 / 10
AI naming: 46 / 100
Agent readiness: 35 / 100
AI adoption: 0 / 100

Named in Kymera Therapeutics, Inc.’s annual report 9

GILEAD SCIENCES, INC. (GILD)Customer7.7
“The Company evaluated the Gilead Agreement under ASC 606, Revenue from Contracts with Customers, and determined that the arrangement represents a contract with a customer.” SEC filing
GILEAD SCIENCES, INC. (GILD)Licensor7.7
“Option and license agreement with Gilead Sciences” SEC filing
GILEAD SCIENCES, INC. (GILD)Partner7.7
“For example, we granted our collaboration partner Gilead an exclusive option for an exclusive license with respect to our CDK2 program, and future payments under our licensing arrangement with Gilead are contingent upon Gilead's exercise of this option.” SEC filing
JOHNSON & JOHNSON (JNJ)Partner7.7
“In particular, several pharmaceutical companies have announced partnerships around programs targeting STAT6, including Sanofi, Johnson & Johnson and Gilead.” SEC filing
PFIZER INC (PFE)Partner7.7
“In particular, several pharmaceutical companies have announced partnerships around programs targeting STAT6, and/or have their own internal STAT6 programs, including Gilead Sciences, Inc, Johnson & Johnson, Pfizer and Sanofi.” SEC filing
Sanofi (SNY)Licensor6.7
“We are dependent on patents, know-how and proprietary technology, both our own and in-licensed from Sanofi and other collaborators.” SEC filing
Sanofi (SNY)Partner6.7
“We are collaborating with Sanofi on the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields.” SEC filing
Sanofi (SNY)Supplier6.7
“The Company analyzed the discovery and preclinical research activities as well as the exclusive license grants under the Sanofi Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC 606.” SEC filing
Vertex Pharmaceuticals, Inc.Partner4.0
“Our only revenues have been derived from research collaboration arrangements with Vertex Pharmaceuticals Incorporated, or Vertex,, Sanofi and Gilead.” SEC filing

Companies whose annual reports name Kymera Therapeutics, Inc. 1

GILEAD SCIENCES, INC. (GILD)names it as licensor7.7
“• Entered into an exclusive option and license agreement with Kymera Therapeutics, Inc. to develop novel oral molecular glue CDK2 degraders with broad oncology treatment potential.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.